


SUPPLEMENTARY FIGURES



Supp. Figure 1. Urinary platinum excretion and gene expression changes in Oct1(-/-) and Oct2(-/-) mice. Effect of (A) Oct1 (■) and (B) Oct2 (●) deficiency on renal handling of cisplatin in mice. The cumulative excretion of cisplatin after drug administration (10 mg/kg; i.p.) was unchanged in Oct1(-/-), Oct2(-/-), and wildtype mice ($n = 4-5/\text{group}$). Data are shown as mean values; error bars represent \pm standard error.





Figure 2. Histopathology in wildtype and Oct1/2(-/-) mice after treatment with cisplatin. Tissue groups represent wildtype (top) and Oct1/2(-/-) (bottom) (A) Brain, (B) Bone marrow, (C) Colon, (D) Heart, (E) Liver, (F) Lung, (G) Skin, (H) Spleen, (I) Small Intestine, (J) Testicle 72 hours after cisplatin treatment.



Supp. Figure 3. Gene expression changes in the copper transporter 1 (Ctr1; *Slc31a1*) in the kidney of male Oct1/2(-/-) and wildtype mice ($n = 3/\text{group}$) before and after treatment with cisplatin (10 mg/kg, i.p.) as determined by the Affymetric mouse 430v2 genechip microarray. Samples were obtained at 72 hours after drug administration.